WO1995013811A1 - Utilisation de derives de thiazolidine substitues pour le traitement de l'elevation de la pression intra-oculaire - Google Patents
Utilisation de derives de thiazolidine substitues pour le traitement de l'elevation de la pression intra-oculaire Download PDFInfo
- Publication number
- WO1995013811A1 WO1995013811A1 PCT/EP1994/003758 EP9403758W WO9513811A1 WO 1995013811 A1 WO1995013811 A1 WO 1995013811A1 EP 9403758 W EP9403758 W EP 9403758W WO 9513811 A1 WO9513811 A1 WO 9513811A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thiazolidine
- phenyl
- carboxy
- alkyl
- nitroxyethoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
Definitions
- the invention relates to the new use of substituted thiazolidine derivatives for the manufacture of medicaments for the treatment of eye diseases.
- W092 / 04337 known compounds are outstandingly suitable for the treatment of (pathologically increased) intraocular pressure.
- the invention relates to the use of compounds of the formula I (see attached formula sheet), in which
- R1 is hydrogen (H) or 1-4C-alkyl
- R2 is hydrogen (H), 1-6C-alkyl, 4-8C-cycloalkyl, phenyl-1-3C-alkyl or a radical of the formula II (see attached formula sheet), in which
- R9, R10 and R11 are the same or different and are hydrogen (H), 1-6C-alkyl, 1-6C-alkoxy, 4-8C-cycloalkyl, 4-8C-cycloalkoxy.
- Halogen. Represent nitro, nitryloxy-2-6C-alkoxy, nitryloxy-4-8C-cycloalkoxy, nitryloxy1-2C-alkyl-4-8C-cycloalkyl-1-2C-alkoxy or a group of the formula -W-C0-Y-R12, in the
- W is a bond or a group of the formula -OCHp-
- Y represents an oxygen atom (0) or an imino group (NH) and R12 represents hydrogen (H), 1-4C-alkyl, 4-8C-cycloalkyl, nitryloxy-2-6C-alkyl or nitryloxy-4-8C-cycloalkyl,
- R3 and R4 are hydrogen (H) or 1-4C-alkyl
- R5 is hydrogen (H) or a group of the formula -CO-Z-R7, in which Z is an oxygen atom (0) or an imino group (NH) and
- R7 hydrogen (H), 1-4C-alkyl, 4-8C-cycloalkyl, nitryloxy-2-6C-alkyl, nitryloxy-4-8C-cycloalkyl, nitryloxy-1-2C-alkyl-4-8C-cycloalkyl-1- 2C-alkyl or 4-nitryloxy-2,6-dioxabicyclo [3.3.0] oct-8-yl,
- R6 is hydrogen (H) or a group of the formula -X-R8 in which
- R8 represents 1-4C-alkyl, 4-8C-cycloalkyl, nitryloxy-2-6C-alkyl, nitryloxy-4-8C-cycloalkyl, phenyl or 1-4C-AI alkylphenyl,
- 1-4C-Alkyl stands for straight-chain or branched AI kyl residues with 1 to 4 carbon atoms. Examples include the butyl, iso-butyl, sec-butyl, tert-butyl, propyl, isopropyl, ethyl and especially the methyl radical.
- 1-6C-Alkyl also includes straight-chain or branched alkyl radicals having 5 or 6 carbon atoms. Examples include the pentyl, isopentyl, neopentyl and hexyl radicals.
- 4-8C-Cycloalkyl stands for cyclic alkyl radicals with 4 to 8 carbon atoms, that is for the cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl radical.
- Phenyl-1-3C-alkyl stands for 1-3C-alkyl radicals which are substituted by a phenyl radical.
- a phenyl radical for example, the phenyl propyl, the phenylethyl and the benzyl radical may be mentioned.
- 1-6C-alkoxy radicals contain one of the 1-6C-alkyl radicals mentioned above. The methoxy and ethoxy radicals are preferred.
- 4-8C-cycloalkoxy radicals contain one of the 4-8C-cycloalkyl radicals mentioned above.
- the cyclopentyloxy and the cyclohexyloxy radical may be mentioned.
- Halogen in the sense of the present invention is bromine, chlorine and fluorine.
- Nitryloxy-2-6C-alkoxy radicals are straight-chain or branched 2-6C-alkoxy radicals to which a nitryloxy group (-O-NO 2 ) is attached.
- Exemplary preferred nitryloxy-2-6C-alkoxy radicals are the 2-nitryloxyethoxy group (-OCH 2 CH 2 -O-NO 2 ), the 3-nitryloxypropoxy group (-O- (CH 2 ) 3 -O-NO 2 ), the 4th -Nitryloxybutoxyrios (-O- (CH 2 ) 4 -O-NO 2 ), the 2-nitryloxypropoxy group [-O-CH 2 -CH (CH 3 ) -O-NO 2 ] and the 2,2-dimethyl-3- nitryloxypropoxy group
- Nitryloxy-4-8C-cycloalkoxy radicals are 4-8C-cycloalkoxy radicals to which a nitryloxy group is attached.
- the 4-nitryloxycyclohexyloxy radical may be mentioned.
- Nitryloxy-1-2C-alkyl-4-8C-cycloalkyl-1-2C-alkoxy radicals are 4-8C-cycloalkyl radicals which are bonded to a 1-2C-alkoxy radical and to which a nitryloxy-1-2C-alkyl radical is bound is.
- An exemplary preferred nitryloxy-1-2C-alkyl-4-8C-cycloalkyl-1-2C-alkoxy radical is the nitroxymethyl - (trans) -cyclohexylmethoxy radical [-OCH 2 - (C 6 H 10 ) -CH 2 -O-NO 2 ].
- Suitable pharmacologically acceptable salts for compounds of the formula I are preferably all acid addition salts with inorganic and organic acids commonly used in galenics. Suitable as such are water-soluble and water-insoluble acid addition salts with acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, Nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2- (4-hydroxybenzoyl) -benzoic acid, butyric acid, sulfosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenic acid, toluenic acid 3-hydroxy-2-naphthoic acid, the acids used in salt production - depending on whether it is a mono- or polybasic acid and which salt is desired - in an equimolar or a different quantity ratio.
- acids
- the compounds of the formula I are used in particular in the form of those medicaments which are suitable for the treatment of eye diseases.
- suitable pharmaceutical formulations include, for example, emulsions, suspensions, ointments or solutions (e.g. eye drops) in which the active substance content is advantageously between 0.01 and 99%.
- auxiliaries suitable for the desired pharmaceutical formulations on the basis of his specialist knowledge.
- solvents and other active ingredient carriers for example antioxidants, dispersants, emulsifiers, preservatives, solubilizers or permeation promoters can be used.
- the reduction in intraocular pressure in female New Zealand albino rabbits was determined using conventional methods.
- the substances to be examined were dropped in 0.05% solution (50 ⁇ l) into one eye, while a solution of the
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Utilisation de composés de la formule (I), dans laquelle les substituants ont la signification indiquée dans la description, et utilisation de leurs sels compatibles sur le plan pharmacologique pour la fabrication de produits pharmaceutiques destinés au traitement de l'élévation pathologique de la pression intra-oculaire.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU81076/94A AU8107694A (en) | 1993-11-17 | 1994-11-12 | Use of substituted thiazolidine derivatives in the treatment of raised intraocular pressure |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH342893 | 1993-11-17 | ||
CH3428/93-4 | 1993-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995013811A1 true WO1995013811A1 (fr) | 1995-05-26 |
Family
ID=4255768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1994/003758 WO1995013811A1 (fr) | 1993-11-17 | 1994-11-12 | Utilisation de derives de thiazolidine substitues pour le traitement de l'elevation de la pression intra-oculaire |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU8107694A (fr) |
WO (1) | WO1995013811A1 (fr) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000009106A2 (fr) * | 1998-08-14 | 2000-02-24 | Gpi Nil Holdings, Inc. | Acides carboxyliques et isosteres de composes a noyau heterocyclique possedant plusieurs heteroatomes et destines a des troubles de la vision et de la memoire |
US6093696A (en) * | 1997-05-30 | 2000-07-25 | Celltech Therapeutics, Limited | Tyrosine derivatives |
US6110945A (en) * | 1998-06-03 | 2000-08-29 | Celltech Therapeutics Limited | Aromatic amine derivatives |
US6274577B1 (en) | 1998-09-30 | 2001-08-14 | Celltech Therapeutics Limited | Benzodiazepines |
US6319922B1 (en) | 1998-11-23 | 2001-11-20 | Celltech Therapeutics Limited | Propanoic acid derivatives |
US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
US6329362B1 (en) | 1998-03-16 | 2001-12-11 | Celltech Therapeutics Limited | Cinnamic acid derivatives |
US6348463B1 (en) | 1998-09-28 | 2002-02-19 | Celltech Therapeutics Limited | Phenylalanine derivatives |
US6362204B1 (en) | 1998-05-22 | 2002-03-26 | Celltech Therapeutics, Ltd | Phenylalanine derivatives |
US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
US6465471B1 (en) | 1998-07-03 | 2002-10-15 | Celltech Therapeutics Limited | Cinnamic acid derivatives |
US6469025B1 (en) | 2000-08-02 | 2002-10-22 | Celltech R&D Ltd. | 3-substituted isoquinolin-1-yl derivatives |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
US6555562B1 (en) | 1998-02-26 | 2003-04-29 | Celltech R&D Limited | Phenylalanine derivatives |
US6610700B2 (en) | 2000-04-17 | 2003-08-26 | Celltech R & D Limited | Enamine derivatives |
US6740654B2 (en) | 2000-07-07 | 2004-05-25 | Celltech R & D Limited | Squaric acid derivatives |
US6953798B1 (en) | 1998-11-30 | 2005-10-11 | Celltech R&D Limited | β-alanine derivates |
US20100183629A1 (en) * | 2006-07-25 | 2010-07-22 | Alcon Research, Ltd. | Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992004337A1 (fr) * | 1990-09-05 | 1992-03-19 | Cedona Pharmaceuticals Bv | Derives de thiazolidine |
-
1994
- 1994-11-12 WO PCT/EP1994/003758 patent/WO1995013811A1/fr active Application Filing
- 1994-11-12 AU AU81076/94A patent/AU8107694A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992004337A1 (fr) * | 1990-09-05 | 1992-03-19 | Cedona Pharmaceuticals Bv | Derives de thiazolidine |
Non-Patent Citations (2)
Title |
---|
J.A. NATHANSON: "Nitrovasodilators as a new class of ocular hypertensives.", J. PHARMACOL. EXP. THER, vol. 260, no. 3, 1992, pages 956 - 965 * |
L.Z. BITO: "Comparison of the ocular hypotensive efficacy of eicosanoids and related compounds.", EXP. EYE RES., vol. 38, no. 2, 1984, pages 181 - 194 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6093696A (en) * | 1997-05-30 | 2000-07-25 | Celltech Therapeutics, Limited | Tyrosine derivatives |
US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
US6555562B1 (en) | 1998-02-26 | 2003-04-29 | Celltech R&D Limited | Phenylalanine derivatives |
US6329362B1 (en) | 1998-03-16 | 2001-12-11 | Celltech Therapeutics Limited | Cinnamic acid derivatives |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
US6362204B1 (en) | 1998-05-22 | 2002-03-26 | Celltech Therapeutics, Ltd | Phenylalanine derivatives |
US6110945A (en) * | 1998-06-03 | 2000-08-29 | Celltech Therapeutics Limited | Aromatic amine derivatives |
US6369229B1 (en) | 1998-06-03 | 2002-04-09 | Celltech Therapeutics, Limited | Pyridylalanine derivatives |
US6465471B1 (en) | 1998-07-03 | 2002-10-15 | Celltech Therapeutics Limited | Cinnamic acid derivatives |
WO2000009106A2 (fr) * | 1998-08-14 | 2000-02-24 | Gpi Nil Holdings, Inc. | Acides carboxyliques et isosteres de composes a noyau heterocyclique possedant plusieurs heteroatomes et destines a des troubles de la vision et de la memoire |
WO2000009106A3 (fr) * | 1998-08-14 | 2000-10-12 | Guilford Pharm Inc | Acides carboxyliques et isosteres de composes a noyau heterocyclique possedant plusieurs heteroatomes et destines a des troubles de la vision et de la memoire |
US6348463B1 (en) | 1998-09-28 | 2002-02-19 | Celltech Therapeutics Limited | Phenylalanine derivatives |
US6677339B2 (en) | 1998-09-28 | 2004-01-13 | Celltech R & D Limited | Phenylalanine derivatives |
US6274577B1 (en) | 1998-09-30 | 2001-08-14 | Celltech Therapeutics Limited | Benzodiazepines |
US6319922B1 (en) | 1998-11-23 | 2001-11-20 | Celltech Therapeutics Limited | Propanoic acid derivatives |
US6953798B1 (en) | 1998-11-30 | 2005-10-11 | Celltech R&D Limited | β-alanine derivates |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
US6610700B2 (en) | 2000-04-17 | 2003-08-26 | Celltech R & D Limited | Enamine derivatives |
US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
US6740654B2 (en) | 2000-07-07 | 2004-05-25 | Celltech R & D Limited | Squaric acid derivatives |
US6469025B1 (en) | 2000-08-02 | 2002-10-22 | Celltech R&D Ltd. | 3-substituted isoquinolin-1-yl derivatives |
US20100183629A1 (en) * | 2006-07-25 | 2010-07-22 | Alcon Research, Ltd. | Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders |
Also Published As
Publication number | Publication date |
---|---|
AU8107694A (en) | 1995-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995013811A1 (fr) | Utilisation de derives de thiazolidine substitues pour le traitement de l'elevation de la pression intra-oculaire | |
DE2037610C3 (fr) | ||
DE602004007840T2 (de) | Pyrazolopyrimidinon und ihre Verwendung als PDE-Inhibitoren | |
DE3119051A1 (de) | Mittel zur behandlung der augen | |
DE1518691B1 (de) | 9-(gamma-Methylamino-propyl)-9,10-dihydro-9,10-aethano-anthrazen,seine Salze und Verfahren zu deren Herstellung | |
DE1620449C3 (de) | Substituierte Benzimidazole und Verfahren zu ihrer Herstellung | |
DE1908991C3 (fr) | ||
DE3107933A1 (de) | Substituierte 3-amino-sydnonimine, verfahren zu ihrer herstellung und ihre verwendung | |
DE2123246A1 (de) | Dihydropyndazone | |
DE3010093A1 (de) | 1,1-diphenyl-2-(1.2.4-triazol-1-yl)-aethan-1-ole, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel | |
DE2802864A1 (de) | 3-isobutoxy-2-pyrrolidino-n-phenyl- n-benzylpropylamin, verfahren zu seiner herstellung und es enthaltende arzneimittel | |
EP0207397A2 (fr) | Préparation combinée de dihydropyridine | |
DD150693A5 (de) | Verfahren zur herstellung eines oxytetracyclin-chelats | |
DE2708886A1 (de) | Neue n-substituierte-n'-chlorbenzoylhydrazin-verbindungen | |
EP0695303B1 (fr) | Sels de pyridinium et leur utilisation pour combattre des bacteries helicobacter | |
WO2002018381A1 (fr) | 6,7-dihydro-pyrrolo[3,4-b]pyridin-5-ones a action anti-convulsive et leurs procedes de preparation | |
DE2356005A1 (de) | Neue 7-amino-imidazo eckige klammer auf 1,2-a eckige klammer zu pyrimidine, diese enthaltende arzneimittel sowie verfahren zu deren herstellung | |
DE2022206B2 (de) | Basisch substituierte Diphenylazolyl-essigsäureester, Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende Arzneimittel | |
DE3229539A1 (de) | Neue oxamidsaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel | |
DE1806995C3 (de) | Bisimidazolyl-bisphenylmethane und deren Salze | |
DE2131826A1 (de) | Neue organische Verbindungen und Verfahren zu deren Herstellung | |
EP1434761B1 (fr) | Sels de derives de la guanidine et preparations pharmaceutiques associees | |
AT236976B (de) | Verfahren zur Herstellung von neuen Benzolsulfonylharnstoffen | |
WO1995013812A1 (fr) | Utilisation de dihydro-1,4 pyridine substituee pour reduire la pression intra-oculaire | |
DE1770939C3 (de) | N-<Diphenyl-pyridyl-methyl) - imidazole und deren Salze |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BY CA CN CZ EE FI HU JP KR LT LV NO NZ PL RO RU SI SK UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |